Seize the innovative leading value and explore the investment opportunities in Hong Kong stocks in the pharmaceutical sector after the deep pullback.

Since the beginning of this year, in the pharmaceuticals Sector, the Hong Kong stock market has demonstrated more cost-effective investment value compared to the A-shares.

Zhitong Finance06:34 ET

Exchange-Traded Funds, Equity Futures Lower Pre-Bell Friday as Markets Sluggishly Move to Year-End

MT NewswiresDec 27 08:06 ET

BeiGene Gains FDA Nod for TEVIMBRA, Marking Key Progress in Oncology Treatments

BenzingaDec 27 06:01 ET

TEVIMBRA Approved in U.S. for First-line Treatment of Gastric and Gastroesophageal Junction Cancers in Combination With Chemotherapy

BusinesswireDec 27 06:00 ET

Express News | Tevimbra Approved in U.S. for First-Line Treatment of Gastric and Gastroesophageal Junction Cancers in Combination With Chemotherapy

ReutersDec 27 06:00 ET

Kaiyuan Securities: Each subtype of hematological tumors has the potential to hatch "heavyweight bomb" drugs. Pay attention to Innovative Drugs companies.

The subtype of blood tumors is less aggressive with a longer treatment cycle, generally requiring long-term medication. Patients have relatively high viscosity and the potential for the emergence of "blockbuster" drugs.

Zhitong FinanceDec 25 21:48 ET